RICTOR and cancer: RICTOR was most frequently altered in bone-metastatic breast cancer samples (10/201 = 5%), which is consistent with a previous study showing that bone-derived mesenchymal stem cells (MSCs) with aberrant RICTOR expression inhibited breast cancer bone metastasis by repressing osteolytic destruction and cancer-associated fibroblasts32.